(PharmaNewsWire.Com, May 16, 2017 ) According to a latest pipeline assessment on the Glomerulonephritis, it has been analysed that the main factors that result in glomerulonephritis are family history, strep throat, immune diseases, such as lupus, type 1 & type 2 diabetes and viruses, such as hepatitis B virus, HIV and hepatitis C virus. The rapid increase in these factors has directly augmented the glomerulonephritis disease. Recently, a detailed analysis has been added to Market Research Hub’s vast database (MRH), and titled as “Glomerulonephritis - Pipeline Review, H1 2017”. The report provides a detailed analysis of Glomerulonephritis by main industries and major drugs.
Glomerulonephritis is medical disease that damages the part of the kidney that filters blood. It is a serious illness that can be life-threatening and requires immediate treatment, the condition is of two type that includes acute, and chronic. The early symptoms of acute glomerulonephritis are puffiness of face in the morning, blood in the urine and urinating less than usual. The chronic form may develop silently over several years that consequently leads to complete kidney failure. The chronic form symptoms include blood or protein in the urine, high blood pressure, swelling of your ankles or face, frequent urination during night time and very bubbly or foamy urine.
The report starts with the Glomerulonephritis overview and its therapeutics development. Further, the companies and universities/institutes are considered for this pipeline analysis; and are overviewed along with the products under development by the companies and universities. The glomerulonephritis therapeutics are further assessed by the target, mechanism of action, route of administration and molecular type. Moving on, the leading companies involved in therapeutic development for glomerulonephritis are listed with top players including Achillion Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Biogen Inc., BLR Bio LLC, ChemoCentryx Inc., Dimerix Bioscience Pty Ltd, GlaxoSmithKline Plc, Mallinckrodt Plc, Omeros Corp, Pfizer Inc., Pharmalink AB, Ra Pharmaceuticals Inc., Retrophin Inc., Rigel Pharmaceuticals Inc., Shire Plc and Visterra Inc.
This detailed study also includes the major drugs listed for glomerulonephritis that consist of (irbesartan + propagermanium), ACH-4471, AMY-101, AVX-002, BaxB-01, BaxG-03, belimumab, blisibimod, BLR-400, budesonide, CCX-140, corticotropin, eculizumab, fostamatinib disodium, iosmapimod, monoclonal antibodies to inhibit ITGAM for cardiovascular, immunology and Kidney Diseases. The other drugs are OMS-721, PF-1355, recombinant enzyme for immunoglobulin, rituximab, SHP-627, sparsentan, TM-5484, vaccine to target CD40 for membranous glomerulonephritis, VAR-200, VIS-649, small molecule to inhibit factor D for PNH and dense deposit disease, and other. The report is followed by the press release and news that further provide the facts andfigures for Glomerulonephritis and concluded with the list of tables that elaborate the research.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
